FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia

AJ Mead, DC Linch, Robert Hills, Keith Wheatley, AK Burnett, RE Gale

Research output: Contribution to journalArticle

215 Citations (Scopus)

Abstract

The prognostic impact of tyrosine kinase domain (TKD) mutations of the fms-like tyrosine kinase-3 (FLT3) gene in acute myeloid leukemia (AML) is currently uncertain. To resolve this issue we screened 1107 young adult nonacute promyelocytic leukemia AML patients with known FLT3 internal tandem duplication (ITD) status for FLT3/TKDs; they were detected in 127 (11%) cases. Mutations were associated with a high white cell count (P =.006) and patients with inv(1 6) (P =.005) but were infrequent in patients with adverse cytogenetics and secondary AML. Overall survival (OS) at 5 years was 53% and 37% for FLT3/TKD mutant and wild-type patients respectively (odds ratio, 0.72; 95% confidence interval, 0.58 to 0.89; P =.002). For both the cumulative incidence of relapse and OS the difference in outcome between and FLT3/TKDs was highly significant (P
Original languageEnglish
Pages (from-to)1262-1270
Number of pages9
JournalBlood
Volume110
Issue number4
DOIs
Publication statusPublished - 1 Aug 2007

Fingerprint

Dive into the research topics of 'FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this